Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog

Endocrine

Volumn 39, Issue 3, 2011, Pages 229-234

  Johnson, Kathryn M S ^a,b   Farmer, Tiffany ^a   Schurr, Kathleen ^b   Patrick Donahue, E ^a   Farmer, Ben ^a   Neal, Doss ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BELOIT COLLEGE   (United States)

Author keywords

Gastric emptying; Incretin effect; Insulin secretion

Indexed keywords

EXENDIN [9-39]; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; INSULIN; PARACETAMOL; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACCLIMATIZATION; ANIMAL EXPERIMENT; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DOG; EXPERIMENTAL DOG; FEMALE; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HORMONE RELEASE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RECEPTOR BLOCKING; STOMACH EMPTYING;

EID: 79959954923     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9441-x     Document Type: Article

References (21)

1. L. L. Baggio, D. J. Drucker, Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157(2007) (Pubitemid 46711096)
2. V. Ionut, I. F. Liberty, K. Hucking, M. Lottati, D. Stefanovski, D. Zheng, R. N. Bergman, Exogenously imposed postprandiallike rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am. J. Physiol. Endocrinol. Metab. 291, E779-E785 (2006) (Pubitemid 44484920)
3. K. M. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, A. D. Cherrington, Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am. J. Physiol. Endocrinol. Metab. 293, E1085-E1091 (2007) (Pubitemid 47535841)
4. K. M. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, A. D. Cherrington, Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization. Am. J. Physiol. Endocrinol. Metab. 294, E380-E384 (2008) (Pubitemid 351231465)
5. V. Ionut, K. Hucking, I. F. Liberty, R. N. Bergman, Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48, 967-975(2005) (Pubitemid 40767991)
6. L. Hansen, C. F. Deacon, C. Orskov, J. J. Holst, Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140, 5356-5363(1999)
7. H. E. Raybould, Mechanisms of CCK signaling from gut to brain. Curr. Opin. Pharmacol. 7, 570-574(2007) (Pubitemid 350177553)
8. R. C. Heading, J. Nimmo, L. F. Prescott, P. Tothill, The dependence of paracetamol absorption on the rate of gastric emptying. Br. J. Pharmacol. 47, 415-421(1973)
9. M. Nishizawa, M. C. Moore, M. Shiota, S. M. Gustavson, W. L. Snead, D. W. Neal, A. D. Cherrington, Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am. J. Physiol. Endocrinol. Metab. 284, E1027-E1036 (2003) (Pubitemid 36444040)
10. C. M. Edwards, J. F. Todd, M. Mahmoudi, Z. Wang, R. M. Wang, M. A. Ghatei, S. R. Bloom, Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48, 86-93(1999) (Pubitemid 29019356)
11. V. Ionut, D. Zheng, D. Stefanovski, R. N. Bergman, Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am. J. Physiol. Endocrinol. Metab. 295(2), E269-E277 (2008)
12. D. K. Sindelar, J. H. Balcom, C. A. Chu, D. W. Neal, A. D. Cherrington, A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 45, 1594-1604(1996) (Pubitemid 26357554)
13. S. E. O'Connell, F. J. Zurzola, A rapid quantitative determination of acetaminophen in plasma. J. Pharm. Sci. 71, 1291-1294(1982) (Pubitemid 13230078)
14. B. Ameer, D. J. Greenblatt, M. Divoll, D. R. Abernethy, L. Shargel, High-performance liquid chromatographic determination of acetaminophen in plasma: single-dose pharmacokinetic studies. J. Chromatogr. 226, 224-230(1981) (Pubitemid 12223719)
15. M. Salehi, B. Aulinger, R. L. Prigeon, D. A. D'Alessio, Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 59, 1330-1337(2010)
16. D. S. Edgerton, K. M. Stettler, T. Rodewald, B. Farmer, M. Lautz, J. Hastings, W. Snead, M. Scott, A. D. Cherrington, Intraportal exendin delivery increases liver and muscle glucose utilization. Diabetes 55, 406(2006)
17. K. Kawai, S. Suzuki, S. Ohashi, H. Mukai, H. Ohmori, Y. Murayama, K. Yamashita, Comparison of the effects of glucagon-like peptide-1-(1-37) and - (7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124, 1768-1773(1989) (Pubitemid 19105444)
18. M. P. van der Burg, O. R. Guicherit, M. Frolich, H. G. Gooszen, Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets. Regul. Pept. 60, 61-67(1995)
19. S. Delgado-Aros, D. Y. Kim, D. D. Burton, G. M. Thomforde, D. Stephens, B. H. Brinkmann, A. Vella, M. Camilleri, Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G424-G431 (2002) (Pubitemid 34651657)
20. M. C. Moore, U. Werner, M. S. Smith, T. D. Rodewald, A. D. Cherrington, Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog. Diabetologia 40(Suppl 1), 242 (2007)
21. H. R. Davis Jr., D. E. Mullins, J. M. Pines, L. M. Hoos, C. F. France, D. S. Compton, M. P. Graziano, E. J. Sybertz, C. D. Strader, M. Van Heek, Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obes. Res. 6, 147-156(1998) (Pubitemid 128679656)